

## Some hematological parameters and the prognostic value of CD4, CD8 and total lymphocyte counts and CD4/CD8 cell count ratio in healthy HIV sero-negative, healthy HIV sero-positive and AIDS subjects in Port Harcourt, Nigeria

*Nijerya'da (Port Harcourt) sağlıklı HIV seronegatif, sağlıklı HIV seropozitif ve AIDS hastası olgularda CD4, CD8 ve toplam lenfosit sayısı ve CD4/CD8 hücre sayısı oranının prognostik değeri ve bazı hematolojik parametreler*

Victor Dapper<sup>1</sup>, Pedro Emem-Chioma<sup>1</sup>, Blessing Didia<sup>2</sup>

<sup>1</sup>Department of Human Physiology, Faculty of Basic Medical Sciences, College of Health Sciences, University of Port Harcourt, Port Harcourt, Nigeria

<sup>2</sup>Department of Anatomy, Faculty of Basic Medical Sciences, College of Health Sciences, University of Port Harcourt, Port Harcourt, Nigeria

### Abstract

**Objective:** The present study attempts to determine normal values of CD4, CD8, CD4/CD8 ratio, total WBC and differential counts, hematocrit and total lymphocyte count (TLC) in healthy HIV sero-negative and sero-positive subjects, and to assess the prognostic significance of these parameters in these subjects as compared to AIDS subjects.

**Material and Methods:** A total of 300 subjects (147 M, 153 F) aged between 17 and 71 years were recruited into the study. Subjects were separated according to sex and divided into three groups: Group A: healthy HIV sero-negative subjects; Group B: healthy HIV sero-positive newly diagnosed ART-naïve subjects; and Group C: AIDS subjects. CD4 and CD8 counts were determined by flow cytometry; hematocrit was determined using Hawksley micro-capillary tubes; total WBC and differential counts were determined manually with the improved Neubauer counting chamber; and TLC was obtained by multiplying the percentage of lymphocytes by the total WBC count.

**Results:** For male subjects, significant differences were found in CD4 count, CD4/CD8 count ratio, hematocrit, total WBC and TLC, whereas for female subjects, significant differences were found only in CD4 and CD4/CD8 count ratio in the three groups of subjects. In both sexes, however, these parameters were found to be highest in healthy HIV sero-negative subjects and lowest in AIDS subjects, with HIV sero-positive subjects having intermediate values.

**Conclusion:** The results confirm previous reports that the CD4 count and CD4/CD8 count ratio are fairly reliable indicators of the progression of HIV infection. In addition, the results also apparently suggest that the prognostic value of CD8 count is limited and that of TLC possibly sex-dependent. The results could be of importance in our environment since previous reports have been relatively scarce. (*Turk J Hematol 2008; 25: 181-6*)

**Key words:** CD4 counts, CD8 counts, CD4/CD8 ratio, total lymphocyte count, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS).

Received: May 21, 2008

Accepted: September 17, 2008

## Özet

**Amaç:** Bu çalışmanın amacı sağlıklı HIV seronegatif ve seropozitif olgularda normal CD4, CD8 değerleri, CD4/CD8 oranı, total lökosit ve periferik yaymadaki kan hücrelerinin sayımları hematokrit ve total lenfosit sayımının (TLS) tespit edilmesi ve AIDS olgularına kıyasla bu kişilerde söz konusu parametrelerin prognostik öneminin değerlendirilmesidir.

**Yöntem ve Gereçler:** Onyediyedi ile 71 yaş aralığındaki toplam 300 olgu (147 E, 153 K) çalışmaya alınmıştır. Olgular cinsiyete göre ayrılmış ve üç gruba bölünmüştür: Grup A: Sağlıklı HIV seronegatif olgular; Grup B: sağlıklı HIV seropozitif (yeni teşhis edilmiş ART-naïve) olgular; ve Grup C: AIDS olgular. CD4 ve CD8 sayımları akış sitometrisi ile; hematokrit Hawksley mikroskopik tüpler ile; total lökosit ve periferik yaymadaki kan hücrelerinin sayımları geliştirilmiş Neubauer sayım kabı kullanılarak manuel olarak tespit edilmiş ve TLS de lenfosit yüzdesinin toplam lökosit sayımı ile çarpılmasıyla elde edilmiştir.

**Bulgular:** Üç çalışma grubunda erkek olgularla ilgili olarak CD4 sayımı, CD4/CD8 sayımının oranı, hematokrit, toplam lökosit ve toplam lenfosit sayımına yönelik anlamlı farklılıklar gözlemlenirken kadın olgularda yalnızca CD4 sayımı ve CD4/CD8 oranında anlamlı farklılıklar bulunmuştur. Ancak her iki cinsiyete yönelik olarak bu parametrelerin en yüksek değerleri HIV seronegatif olgularda ve en düşük değerleri de AIDS olgularında gözlenmiştir. HIV seropozitif olgular ise ara değerlere sahiptir.

**Sonuç:** Elde edilen sonuçlar ile CD4 sayımı ve CD4/CD8 oranının, HIV enfeksiyonunun gelişimine yönelik oldukça güvenilir göstergeler olduğuna dair önceki raporlar onaylanmaktadır. Ayrıca elde edilen sonuçlar ile, CD8 sayımı prognostik değerinin sınırlı olduğu ve toplam lenfosit sayımının ilgili değerinin ise cinsiyete bağlı olduğu açıkça ileri sürülmektedir. Önceki raporlar nispeten sınırlı olduğundan elde edilen sonuçlar son derece önem taşımaktadır.

(Turk J Hematol 2008; 25: 181-6)

**Anahtar kelimeler:** CD4 sayımı, CD8 sayımı, CD4/CD8 oranı, toplam lenfosit sayımı, insan bağışıklık yetmezlik virüsü (HIV), edinilmiş bağışıklık yetmezlik belirtisi (AIDS).

Geliş tarihi: 21 Mayıs 2008

Kabul tarihi: 17 Eylül 2008

## Introduction

Since its identification in 1981, human immunodeficiency virus (HIV) infection and the associated acquired immunodeficiency syndrome (AIDS) remain a major health burden globally. Recent estimates indicate that over 35 million people are affected worldwide, with mortality counts of over 20 million [1]. About 70% of these deaths have occurred in sub-Saharan Africa [1], where the burden of disease is high and poverty an important accomplice. In Nigeria, the current national average HIV seroprevalence rate is estimated at about 4.4%, with Rivers State predictably having a higher rate of 5.4% [2]. This is possibly so following the recent rapid urbanization of Port Harcourt, the capital of Rivers State, due to influx of multinational concerns involved with petroleum exploitation and exploration [3].

In individuals with HIV infection, assessment of CD<sub>4</sub> and CD<sub>8</sub> cell counts is fairly common and they are routine indices for the evaluation of immune status and decision to initiate anti-retroviral drug therapy (ART) [4]. The CD<sub>4</sub> cell counts of healthy HIV sero-negative Caucasians have been reported to be between 500 and 1500 cells/ $\mu$ l, while the CD<sub>8</sub> cell count ranges lower, between 300 and 1000 cells/ $\mu$ l [5]. However, significant geographical and racial differences have been reported in CD<sub>4</sub> count between Asians and Caucasians [6] and even amongst healthy Africans of different countries [7-9]. Racial differences have also been established in white blood cell (WBC) counts between Africans and Caucasians, with a leuko-neutropenia seen in the Africans [10].

With recent up-scaling of ART in developing countries, including Nigeria, and the resultant anticipated increase in the number of individuals accessing ART, determination of CD<sub>4</sub> cell

count would expectedly become more frequent in Nigeria. However, with the relatively high cost of CD<sub>4</sub> cell count determination, total lymphocyte count (TLC) has been suggested as an alternative in situations where facilities for CD<sub>4</sub> cell count are not readily available or resources are limited. This is because TLC is easily obtained from routine complete blood cell counts by multiplying the percentage of lymphocytes by the WBC count [11,12]. However, a number of reports have suggested an inconsistency in the correlations between total lymphocyte and CD<sub>4</sub> cell counts [13].

Given that, in our environment, reports on this subject are relatively scarce, the present study attempted to determine values of CD<sub>4</sub>, CD<sub>8</sub>, total lymphocyte, total WBC and differential cell counts in healthy HIV sero-negative, healthy HIV sero-positive and in persons with AIDS. The study also determined the CD<sub>4</sub>/CD<sub>8</sub> cell count ratio and attempted to assess the possible prognostic value of these parameters using these three groups of subjects. In addition, the study attempts to establish normative values of these parameters, in our environment, for healthy HIV sero-negative and healthy HIV sero-positive subjects who have yet to commence ART. This could possibly assist Nigerian physicians with the assessment and management of HIV infection in affected individuals.

## Materials and Methods

**Subjects:** A total of 300 subjects (147 M, 153 F; age range: 17-71 years) were recruited into the study. Subjects were separated according to sex and were further divided into three groups: Group A [controls] consisted of healthy HIV sero-negative subjects, Group B consisted of healthy HIV sero-positive

subjects, and Group C consisted of AIDS subjects. Groups B subjects were newly diagnosed subjects yet to commence ART. Groups B and C were attending the HIV clinic of a tertiary health care facility in Port Harcourt, southeastern Nigeria; Group A [control] subjects were apparently healthy staff and students of the University of Port Harcourt, Nigeria. Each control subject was examined and no evidence of acute or chronic infections or any hematologic, cardiovascular or metabolic disease likely to influence any of the hematological parameters under investigation was found. All subjects gave informed consent before recruitment into the study; ethical clearance was obtained from our institutional ethics committee. All pregnant female subjects were excluded from the study.

**Methods:** Five milliliters of venous blood was collected from each subject from an antecubital vein with the subject comfortably seated and with minimum stasis. The blood was immediately transferred into EDTA specimen bottles and carefully mixed. All blood specimens were collected between 9 a.m. and 12 noon each day and analyzed within 2 hours of collection.

The HIV status of each subject was determined routinely using the Chembio HIV 1/2 Stat-pak assay kit (Chembio Diagnostic Systems Incorporated, USA). The CD<sub>4</sub> cell and the CD<sub>8</sub> cell counts were both determined by flow cytometry using the Partec Cytoflow counter FMC system (Partec GmbH, 2006).

CD<sub>4</sub>/CD<sub>8</sub> count ratio for each subject was obtained from the product of dividing the CD<sub>4</sub> cell count by the CD<sub>8</sub> cell count. Hematocrit was determined using Hawksley micro-capillary tubes centrifuged at 3000 rpm for 10 minutes; the mean of two separate readings was taken as the hematocrit value. Total WBC and differential WBC counts were determined manually using the improved Neubauer counting chamber [14]. TLC was obtained by multiplying the percentage of lymphocytes by the total WBC count [11,12].

**Statistics:** The results obtained are expressed as means  $\pm$  standard errors of means (SEM); ranges are in parenthesis. Statistical significance was determined using the analysis of variance (ANOVA) or the Student's t-test as appropriate. A p value less than 0.05 ( $p < 0.05$ ) was considered statistically significant.

## Results

The results obtained from the present study for each Group are as shown in Tables 1 and 2 for male and female subjects, respectively.

Table 1 presents the ages, CD<sub>4</sub> and CD<sub>8</sub> counts, CD<sub>4</sub>/CD<sub>8</sub> count ratio, hematocrit, total WBC count, percentage neutrophil, lymphocyte, monocyte, eosinophil and basophil, and TLC for the male subjects involved in the present study. ANOVA showed

**Table 1. Hematological parameters, CD<sub>4</sub> and CD<sub>8</sub> counts and ratio in male HIV sero-negative and sero-positive subjects and AIDS subjects.**

Parameter	Healthy HIV- negative subjects [Group A] [n= 58]	Healthy HIV- positive subjects [Group B] [n=37]	AIDS subjects [Group C] [n= 52]	Significant differences
Age (years)	36.98 $\pm$ 0.98 [18-71]	35.68 $\pm$ 0.87 [17-63]	41.23 $\pm$ 0.99 [19.0-71.0]	No [ $p > 0.05$ ]
CD <sub>4</sub> count (Cells/ $\mu$ l)	1019.0 $\pm$ 23.74 [468.0-1609.0]	545.76 $\pm$ 29.48 [58.0-2285.0]	99.04 $\pm$ 4.36 [12.0-195.0]	Yes [ $p < 0.05$ ]
CD <sub>8</sub> count (Cells/ $\mu$ l)	701.76 $\pm$ 22.99 [137.0-1420.0]	896.30 $\pm$ 36.5 [144.0-2381.0]	781.65 $\pm$ 20.47 [296.0-1385.0]	No [ $p > 0.05$ ]
CD <sub>4</sub> /CD <sub>8</sub> count ratio	1.71 $\pm$ 0.07 [0.44-5.22]	0.79 $\pm$ 0.07 [0.08-4.07]	0.13 $\pm$ 0.01 [0.02-0.29]	Yes [ $p < 0.05$ ]
Hematocrit (%)	40.29 $\pm$ 0.46 [30-58]	31.97 $\pm$ 0.41 [22.0-42.0]	31.02 $\pm$ 0.36 [21.0-38.0]	Yes [ $p < 0.05$ ]
Total WBC count (Cells/ $\mu$ l)	5.56 $\pm$ 0.07 [3.90-7.30]	4.74 $\pm$ 0.09 [2.80-8.30]	4.45 $\pm$ 0.08 [2.60-7.10]	Yes [ $p < 0.05$ ]
Neutrophil count (%)	59.95 $\pm$ 0.56 [45.0-73.0]	57.51 $\pm$ 0.65 [34.0-72.0]	61.75 $\pm$ 0.53 [50.0-78.0]	No [ $p > 0.05$ ]
Lymphocyte count (%)	39.43 $\pm$ 0.55 [26.0-54.0]	40.73 $\pm$ 0.60 [21.0-65.0]	37.35 $\pm$ 0.56 [21.0-49.0]	No [ $p > 0.05$ ]
Monocyte count (%)	0.21 $\pm$ 0.04 [0.0-2.0]	0.22 $\pm$ 0.04 [0.0-2.0]	0.31 $\pm$ 0.05 [0.0-2.0]	No [ $p > 0.05$ ]
Eosinophil count (%)	0.34 $\pm$ 0.05 [0.0-3.0]	0.32 $\pm$ 0.05 [0.0-2.0]	0.40 $\pm$ 0.05 [0.0-2.0]	No [ $p > 0.05$ ]
Basophil count (%)	0.05 $\pm$ 0.02 [0.0-1.0]	-	0.04 $\pm$ 0.02 [0.0-2.0]	No [ $p > 0.05$ ]
Total lymphocyte count (%Cells/ $\mu$ l)	219.1 $\pm$ 4.09 [114.8-340.8]	193.15 $\pm$ 4.62 [86.1-332.0]	168.01 $\pm$ 4.40 [72.6-302.4]	Yes [ $p < 0.05$ ]

Values=mean  $\pm$  SEM, range in parenthesis

that significant differences existed in CD<sub>4</sub> cell count, CD<sub>4</sub>/CD<sub>8</sub> cell count ratio, hematocrit, total WBC count and TLC for male subjects between the three groups under consideration: healthy HIV sero-negative subjects (Group A), healthy HIV sero-positive subjects (Group B) and AIDS subjects (Group C) ( $p < 0.05$ ). Each of these parameters was generally the highest in the healthy HIV sero-negative subjects (Group A) and lowest in the AIDS subjects (Group C), with healthy HIV sero-positive subjects (Group B) having intermediate values.

Similarly, Table 2 presents the values of the investigated parameters in all the female subjects involved in the present study. ANOVA showed that significant differences existed only in CD<sub>4</sub> cell count and CD<sub>4</sub>/CD<sub>8</sub> cell count ratio for the three female groups under consideration ( $p < 0.001$ ). Unlike for male subjects, in female subjects, no significant differences were found in hematocrit, total WBC count and TLC between the three groups under consideration ( $p > 0.001$ ). However, as in male subjects, both CD<sub>4</sub> cell count and CD<sub>4</sub>/CD<sub>8</sub> cell count ratio were highest in the healthy HIV sero-negative subjects (Group A) and lowest in the AIDS subjects (Group C), with healthy HIV sero-positive subjects (Group B) having intermediate values.

Amongst the HIV sero-positive (Group B) subjects, 8 (21.6%) males and 26 (41.3%) females had CD<sub>4</sub> cell counts less than 350 cells/ $\mu$ l. All the AIDS (Group C) subjects were found to have

CD<sub>4</sub> cell counts less than 350 cells/ $\mu$ l. None of the healthy HIV sero-negative (Group A) subjects had CD<sub>4</sub> cell counts less than 350 cells/ $\mu$ l.

## Discussion

The present study presents normative values for CD<sub>4</sub> cell counts, CD<sub>8</sub> cell counts, TLC and CD<sub>4</sub>/CD<sub>8</sub> cell count ratio in healthy HIV sero-negative and healthy HIV sero-positive male and female subjects in Port Harcourt, Nigeria. Previous studies in this regard have been relatively scarce and have focused on the effects of highly active anti-retroviral therapy (HAART) on CD<sub>4</sub> cell count [15]; on use of absolute lymphocyte count as a marker of CD<sub>4</sub> cell count and criteria for initiating ART [16]; and on hematological parameters in HIV-infected Nigerians in Port Harcourt [17].

The CD<sub>4</sub> cell counts obtained in the present study are in the same range as in a recent report in HIV sero-negative Nigerians [18] and are fairly similar to values reported in Caucasians [5,8], Kuwaitis [19], Indians [20], and Tanzanians [21]. However, the CD<sub>8</sub> cell counts obtained in the present study are marginally higher than values reported for Caucasians. The non-significant differences in the CD<sub>8</sub> cell counts between the three groups is at variance with a recent report from Zaria, northern Nigeria, in

**Table 2. Hematological parameters, CD<sub>4</sub> and CD<sub>8</sub> counts and ratio in female HIV sero-negative and sero-positive subjects and AIDS subjects.**

Parameter	Healthy HIV- negative subjects [Group A] [n= 42]	Healthy HIV- positive subjects [Group B] [n=63]	AIDS subjects [Group C] [n=48]	Significant differences
Age (years)	38.93 $\pm$ 1.13 [17-71]	33.86 $\pm$ 0.88 [19-71]	31.73 $\pm$ 0.73 [18-65]	No [ $p > 0.05$ ]
CD <sub>4</sub> count (Cells/ $\mu$ l)	920.52 $\pm$ 24.10 [528.00-1671.00]	451.46 $\pm$ 20.23 [89.00-1377]	94.46 $\pm$ 4.43 [14.00-196.00]	Yes [ $p < 0.05$ ]
CD <sub>8</sub> count (Cells/ $\mu$ l)	834.69 $\pm$ 24.54 [326.00 -1452.00]	804.27 $\pm$ 41.86 [269.00-3943.00]	800.10 $\pm$ 54.88 [58.00-5055.00]	No [ $p > 0.05$ ]
CD <sub>4</sub> /CD <sub>8</sub> count ratio	1.23 $\pm$ 0.04 [0.46-2.41]	0.67 $\pm$ 0.04 [0.15-2.51]	0.19 $\pm$ 0.02 [0.02-1.76]	Yes [ $p < 0.05$ ]
Hematocrit (%)	33.45 $\pm$ 0.31 [24.00-41.00]	30.49 $\pm$ 0.44 [17.00-44.00]	30.38 $\pm$ 0.41 [20.00-44.00]	No [ $p > 0.05$ ]
Total WBC count (Cells/ $\mu$ l)	5.07 $\pm$ 0.10 [3.30-7.80]	4.85 $\pm$ 0.11 [2.80-9.80]	4.82 $\pm$ 0.11 [2.10-8.50]	No [ $p > 0.05$ ]
Neutrophil count (%)	64.74 $\pm$ 0.54 [50.00-78.00]	61.48 $\pm$ 0.71 [37.00-76.00]	61.77 $\pm$ 0.62 [43.00-80.00]	No [ $p > 0.05$ ]
Lymphocyte count (%)	34.33 $\pm$ 0.56 [21.00-48.00]	37.94 $\pm$ 0.75 [22.00-73.00]	37.46 $\pm$ 0.62 [20.00-57.00]	No [ $p > 0.05$ ]
Monocyte count (%)	0.24 $\pm$ 0.04 [0.00-2.00]	0.17 $\pm$ 0.04 [0.00-2.00]	0.21 $\pm$ 0.03 [0.00-1.00]	No [ $p > 0.05$ ]
Eosinophil count (%)	0.62 $\pm$ 0.07 [0.00-4.00]	0.57 $\pm$ 0.07 [0.00-6.00]	0.58 $\pm$ 0.06 [0.00-2.00]	No [ $p > 0.05$ ]
Basophil count (%)	0.12 $\pm$ 0.03 [0.00-2.00]	0.02 $\pm$ 0.01 [0.00-1.00]	-	No [ $p > 0.05$ ]
Total lymphocyte count (%Cells/ $\mu$ l)	178.04 $\pm$ 5.33 [84.0-336.0]	186.7 $\pm$ 6.14 [66-489.1]	177.10 $\pm$ 3.84 [60.9-277.5]	No [ $p > 0.05$ ]

Values=mean  $\pm$  SEM, range in parenthesis

which both CD<sub>4</sub> and CD<sub>8</sub> cell counts were significantly lower in patients compared to controls [22]. However, the significant differences in the CD<sub>4</sub> cell counts seen in the present study are consistent with that report, although our values are lower than the CD<sub>8</sub> cell counts reported in healthy controls [22].

The results of the present study suggest that sex variations apparently do exist in both the pattern of differences and possibly in the prognostic value of the parameters under investigation. For instance, although in both sexes CD<sub>4</sub> cell count and CD<sub>4</sub>/CD<sub>8</sub> cell count ratio consistently showed significant differences in the three groups of subjects, TLC followed a similar pattern only in males. These sex differences in both the TLC and total WBC count seen in the present study are perhaps expected based on the reported sex variations in WBC and neutrophil counts [23] and the reported cyclic variation in WBC population during the normal menstrual cycle [24]. Apparently, menstrual cyclic variations in the WBC count could possibly contribute to obscuring the pattern in females likely leading to a sex distinction. This finding would, however, require further investigation. Perhaps these cyclic variations in females could indeed account for the absence of significant differences in the hematocrit scores in females as opposed to the pattern seen in males. Cyclic changes in the hematocrit scores during the normal menstrual cycle have also been reported by the present authors in Nigerians [25] and have been similarly described in Caucasians [26].

Amongst all the parameters studied, the results of the present study apparently suggest that in our environment, the CD<sub>4</sub> cell count and CD<sub>4</sub>/CD<sub>8</sub> cell count ratio are fairly reliable indicators of the progression of HIV infection in both males and females. This is of possible prognostic value and confirms the findings of previous studies in this regard [27]. The results, however, also suggest that the prognostic value of the CD<sub>8</sub> cell count is limited and that of TLC is possibly sex-dependent.

From the results of the present study, we suggest that Nigerian physicians consider both the CD<sub>4</sub> cell count and the CD<sub>4</sub>/CD<sub>8</sub> cell count ratio more critically in determining the immune status of persons infected with HIV. In addition, the results suggest that the usefulness of TLC in females is limited and therefore can only be used with some caution in place of both the CD<sub>4</sub> cell count and the CD<sub>4</sub>/CD<sub>8</sub> cell count ratio.

In conclusion, the present study attempted to report normative values for CD<sub>4</sub>, CD<sub>8</sub>, TLC, and CD<sub>4</sub>/CD<sub>8</sub> cell count ratio in healthy HIV sero-negative and HIV sero-positive (ART naïve) individuals in Port Harcourt, southeastern Nigeria. In addition, the study reports significantly higher CD<sub>4</sub> cell and CD<sub>4</sub>/CD<sub>8</sub> cell count ratio in healthy HIV sero-negative subjects compared to HIV sero-positive (ART naïve) subjects and AIDS subjects. Our results could be of possible prognostic importance and likely assist in the management of individuals infected with HIV in our environment.

## References

- World Health Organization. UNAIDS 2004 Report on the Global HIV/AIDS epidemic: 4<sup>th</sup> Global Report WHO. Geneva, Switzerland.
- Federal Ministry of Health Nigeria. The 2005 national HIV seroprevalence sentinel survey among pregnant women attending antenatal clinics in Nigeria: summary position paper. April 2006. Abuja, Nigeria.
- Dapper DV, Nwauche CA, Didia BC. Haematological reference values for healthy adults in Port Harcourt, Nigeria. *Port Harcourt Med J* 2006;1:25-8.
- Gange SJ, Lau B, Phair J, Riddler SA, Detels R, Margolick JB. Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy. *AIDS* 2003;17:119-21.
- Highleyman L. Focus on hepatitis. Baseline HCV VL, CD4 percentage predicts HCV treatment response. *IAPAC Mon* 2006;12:375-6.
- Lee BW, Yap HK, Chew FT, Quah TC, Prabhakaran K, Chan GS, Wong SC, Seah CC. Age and sex related changes in lymphocyte subpopulations of healthy Asian subjects: from birth to adulthood. *Cytometry* 1996;26:8-15.
- Levin A, Brubaker G, Shao JS, Kumby D, O'Brien TR, Goedert JJ, Strauss KW, Blattner WA, Hannel I. Determination of T-lymphocyte subsets on site in rural Tanzania: results in HIV-1 infected and non-infected individuals. *Int J STD AIDS* 1996;7:288-91.
- Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, Doorly R, Fontanet AL, Rink de Wit TF. Immunohematological reference ranges for adult Ethiopians. *Clin Diagn Lab Immunol* 1999;6:410-4.
- Tugume SB, Piwowar EM, Lutalo T, Mugenyi PN, Grant RM, Mangeni FW, Pattishall K, Katongole-Mbidde E. Hematological reference ranges among healthy Ugandans. *Clin Diagn Lab Immunol* 1995;2:236-7.
- Ogunranti JO. Non-genetic leuko-neutropenia is related to dietary cholesterol: an experimental model with the rat. *Acta Haematol* 1994;92:61-5.
- Kumarasamy NMA, Flanigan TP, Hemalatha R, Mayer KH, Carpenter CC, Thyrangarajan SP, Solomon S. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. *J Acquir Immune Defic Syndr* 2002;31:378-83.
- Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. *AIDS* 2003;17:541-5.
- van der Ryste E, Kotze M, Joubert G, Steyn M, Pieters H, van der Westhuizen M, van Standen M, Venter C. Correlation among total lymphocyte count, absolute CD4+ count and CD4+ percentage in a group of HIV-1 infected South African patients. *J Acquir Immune Defic Syndr Human Retrovirol* 1998;19:238-44.
- Dacie JV, Lewis SM. *Practical Haematology*. 7th edition. Edinburgh: Churchill Livingstone, 1991.
- Erhabor O, Ejele OA, Nwauche CA. The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience. *Niger J Clin Pract* 2006;9:128-33.
- Erhabor O, Uko EK, Adias T. Absolute lymphocyte count as a marker for CD4 T-lymphocyte count: criterion for initiating ART in HIV infected Nigerians. *Niger J Med* 2006;15:56-9.
- Erhabor O, Ejele OA, Nwauche CA, Buseri FI. Some haematological parameters in human immunodeficiency virus (HIV) infected Africans: the Nigerian perspective. *Niger J Med* 2005;14:33-8.
- Aina O, Dadik J, Charurat M, Amangaman P, Gurumdi S, Mang E, Guyit R, Lar N, Datong P, Daniyam C, Kanki P, Abimiku A. Reference values of CD4 T lymphocytes in human immunodeficiency virus-negative adult Nigerians. *Clin Diagn Lab Immunol* 2005;12:525-30.
- Kaaba SA, Al Fadhli S, Burhamah M, Al Jafar H, Khamis A. Lymphocyte subsets in healthy adult Kuwaiti Arabs with relative benign ethnic neutropenia. *Immunol Lett* 2004;91:49-53.
- Uppal SS, Verma S, Dhot PS. Normal values of CD4 and CD8 lymphocyte subsets in healthy Indian adults and the effects of sex, age, ethnicity and smoking. *Cytometry B Clin Cytom* 2003;52:32-6.
- Urassa WK, Mbena EM, Swai AB, Gaines H, Mhalu FS, Biberfeld G. Lymphocyte subset enumeration in HIV seronegative and HIV-1

- seropositive adults in Dar es Salaam, Tanzania: determination of reference values in males and females and comparison of two flow cytometric methods. *J Immunol Methods* 2003;277:65-74.
22. Onyemelukwe GC, Musa BO. CD4+ and CD8+ lymphocytes and clinical features of HIV seropositive Nigerians on presentation. *Afr J Med Med Sci* 2002;31:229-33.
  23. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. *J Clin Pathol* 1996;49:664-6.
  24. Mathur S, Mathur RS, Goust JM, Williamson HO, Fudenberg HH. Cyclic variations in white cell sub-population in human menstrual cycle: correlations with progesterone and estradiol. *Clin Immunol Immunopathol* 1979;13:246-53.
  25. Dapper DV, Dida BC. Haemorheological changes during the menstrual cycle. *East Afr Med J* 2002;79:181-3.
  26. Brooks DE, Easthope PL. Rheological characteristics of blood through the menstrual cycle. *Biorheology* 1981;18:485-92.
  27. Hoover DR, Graham NM, Chen B, Taylor JM, Phair J, Zhou SY, Munoz A. Effect of CD4+ cell count measurement variability on staging HIV-1 infection. *J Acquir Immune Defic Syndr* 1992;5:794-802.